- Home
- FRBT vs APMD Comparison
FRBT vs APMD Comparison
Compare FRBT & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBT | APMD |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.0M | 895.5M |
| IPO Year | 2026 | 2026 |
Fundamental Metrics
Financial Performance| Metric | FRBT | APMD |
|---|---|---|
| Price | $18.16 | $18.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $22.75 | ★ $50.33 |
| AVG Volume (30 Days) | 105.6K | ★ 456.4K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.17 |
| Revenue Next Year | $20.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.81 | $18.34 |
| 52 Week High | $22.00 | $35.29 |
Technical Indicators
Market Signals| Indicator | FRBT | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 32.65 |
| Support Level | $18.11 | N/A |
| Resistance Level | $19.30 | $30.50 |
| Average True Range (ATR) | 0.84 | 2.66 |
| MACD | 0.05 | -0.60 |
| Stochastic Oscillator | 57.45 | 1.70 |
Price Performance
Historical ComparisonAbout FRBT Forbright Inc. Class A Common Stock
Forbright Inc is a bank holding company. Along with its subsidiaries, it operates as a state chartered non-member bank, which serves the needs of individuals, small and medium sized businesses, and professional concerns. Its services include deposit and retail banking through a digital deposit platform, as well as financing and lending products such as lender finance loans, fund finance loans, healthcare finance loans, real estate loans, working capital facilities, warehouse lines of credit, and term loans.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).